Current Approach to Treating Anemia in LR-MDS

Saeed Sadeghi, MD, shares his current approach to treating anemia in lower-risk myelodysplastic syndromes (LR-MDS), detailing when to choose erythropoiesis-stimulating agents (ESAs) for first-line treatment, conditions for switching therapies, and factors influencing the decision to use luspatercept as a first-line option, including considerations for dose escalation.

EP: 1.Mechanism of Action: Luspatercept vs Epoetin Alfa in LR-MDS

EP: 2.COMMANDS Study Update: Luspatercept vs. Epoetin Alfa in 1L Treatment

EP: 3.Real-World Data on Luspatercept in LR-MDS

EP: 4.Health Care Resource Utilization: Luspatercept vs ESAs in MDS

Now Viewing

EP: 5.Current Approach to Treating Anemia in LR-MDS

Video content above is prompted by the following:

What is your current approach for treating anemia in LR-MDS?

• When would you choose ESAs for first-line treatment?
  • When would you switch therapies? Would you dose escalate before switching to an EMA (eg, second line)?
• What factors lead to a decision to use luspatercept as a first-line treatment?
  • When do you dose escalate?

Recent Videos